Allyson Ocean, M.D.

Medical Oncology

Publications

Abby B. Siegel, Emil I. Cohen, Allyson Ocean, Deborah Lehrer, Alec Goldenberg, Jennifer J. Knox, Helen Chen, Sean Clark-Garvey, Alan Weinberg, John Mandeli, Paul Christos, Madhu Mazumdar, Elizabeta Popa, Robert S. Brown, Jr, Shahin Rafii, Jonathan D. Schwartz. Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, Vol 26, No 18 (June 20), 2008: pp. 2992-2998

Rachel Raab, MD, Joseph A. Sparano, MD, Allyson J. Ocean, MD, Paul Christos,

MPH, MS, Mark Ramirez, MD, Vincent Vinciguerra, MD, and Andreas Kaubisch,

MD. A Phase I Trial of Oblimersen Sodium in Combination With Cisplatin and 5-

Fluorouracil in Patients with Advanced Esophageal, Gastro-Esophageal Junction

and Gastric Carcinoma. In Submission, Annals of Oncology, October 10, 2008

Ocean, AJ, Vahdat, LT. Chemotherapy-Induced Peripheral Neuropathy: Etiology and Emerging Therapies. Journal of Supportive Care in Cancer, 2004 Jul 16.

Ocean, Allyson J., M.D., Women Have Colons, Too: Colorectal Cancer Prevention, Screening, and Treatment Options. Women & Cancer, Winter 2006, p.38-44.

Mark, T., Ocean, AJ. Pancreatic Neuroendocrine Tumor Presenting As Cushing’s Syndrome. In Submission.

Erlotinib for Hepatocellular Carcinoma; Case Report of Effective Tumor Palliation in a Patient with Advanced Cirrhosis. Sheren-Manoff, M, Ocean, A.J., Kinkhabwala, M, Holloway, S., Spellman, J., Matthews, N., Starcic, M., Minnett, K., Sigal, S., In Submission.

Abstracts

Khuri, F, Karp, D, Daly, M, Garcia-Moliner, T, DiPetrillo, T. Bankoff, M,

Ocean AJ. Multidisciplinary Care in Non-Small Cell Lung Cancer: A Financial Analysis of Consecutive Newly Diagnosed Patients. Proc New England Cancer Society, 1995, p. 51.

Lane, ME, Ocean, AJ, Yu, B, Schnoll-Sussman, FH, Cohen-Gould, L, Huang, X,

Xiang, Z, Wadler, S. Ultrastructural Differences Between PS-341 Sensitive and Resistant Human Colon Carcinoma Cell Lines. Proc AACR Molecular Targets and Cancer Therapeutics, 2003, #C86, p.42.

Lane, ME, Xiang, Z, Henschke, C, Yankelevitz, D, Vazquez, M, Kramer, A, Huang, C, Ocean, AJ, Yu, B, Wadler, S. Patterns of Gene Expression in Pulmonary Fine Needle Aspirates (FNA) with Diverse Radiographic Appearances. Proc AACR, 2004.

Lane, ME, Xiang, Z, Henschke, C, Yankelevitz, D, Vazquez, M, Kramer, A, Huang, C, Ocean, AJ, Yu, B, Wadler, S. Patterns of Gene Expression in Pulmonary Fine Needle Aspirates (FNA) with Diverse Radiographic Appearances. Proc ASCO, 2004, Abstract #9587, p. 852.

Ocean, AJ, Lane ME, Huang, X, Xiang, Z, Yu, B, Wadler, S. Genetic Analysis of Proteasome-Related Pathways in PS-341 Resistant Human Colon Cancer Cell Lines. Proc AACR, 2004.

Ocean, AJ, Lane, ME, Xiang, Z, Huang, X, Schnoll-Sussman, F, Holloway, S, Matthews, N, Chen, X, Yu, B, Wright, J, Wadler, S. Genetic Analysis of proteasome-related pathways in advanced gastric adenocarcinomas (AGA) treated on a Phase II study with PS-341 (Velcade, bortezomib) with or without Irinotecan. Proc ASCO, 2004, Abstract # 9717, p.885.

Ocean, AJ, Lane, ME, Xiang, Z, Huang, X, Schnoll-Sussman, F, Holloway, S, Matthews, N, Chen, X, Yu, B, Wright, J, Wadler, S. Phase II study of PS-341 (VELCADE, bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Proc ASCO GI Cancer Symposium, 2005, Abstract #31, p.98.

Ocean, AJ, Lane, ME, Xiang, Z, Huang, X, Schnoll-Sussman, F, Holloway, S, Matthews, N, Chen, X, Yu, B, Wright, J, Wadler, S. Genetic Analysis of proteasome-related pathways in advanced gastric adenocarcinomas (AGA) treated on a Phase II study with PS-341 (Velcade, bortezomib) with or without Irinotecan. Proc ASCO GI Cancer Symposium, 2005, Abstract #69, p.117.

Schwartz, JD, Schwartz, M, Sung M, Lehrer, D, Cohen, E, Kinkhabwala, M, Holloway, S.B., Siegel, A, Ocean, A, Wadler, S. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. Proc Gastrointestinal Cancers Symposium 2006, Abstract #210, p.190.

J. D. Schwartz, M. Schwartz, D. Lehrer, E. Cohen, M. Sung, M. Kinkhabwala, A. Siegel, S. Holloway, A. Ocean, S. Wadler Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4144

A. J. Ocean, F. Schnoll-Sussman, X. E. Chen, R. Keresztes, S. Holloway, N. Matthews, K. O'Brien, P. Christos, M. Mazumdar, S. Wadler Recent results of phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Proc Gastrointestinal Cancers Symposium 2007, Abstract #45.

A. J. Ocean, K. O'Brien, J. Lee, N. Matthews, S. Holloway, P. Christos, T. S. Kung, A. Kaubisch, H. Chen, S. Wadler. Phase II Trial of FOLFOX6, bevacizumab and cetuximab in patients with Colorectal Cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4075

   

Posters/Presentations

Lane, ME, Ocean, AJ, Yu, B, Schnoll-Sussman, FH, Cohen-Gould, L, Huang, X, Xiang, Z, Wadler, S. Ultrastructural Differences Between PS-341 Sensitive and Resistant Human Colon Carcinoma Cell Lines. AACR Molecular Targets and Cancer Therapeutics, 2003, #C86 Poster Presentation.

Lane, ME, Yu, B, Temple K, Nguyen, H, Ocean, AJ, Wadler, S. Combined Treatment with Cisplatin and a Novel Cdk2 Specific Inhibitor (BMS 387032) Results in Cytotoxic Synergy in Human Colon Carcinoma Cells That Is Dependent on Dose, Sequence, and Cyclin D1 Expression, #706, Proc AACR 2003, Poster Presentation.

Ocean, AJ, Lane, ME, Xiang, Z, Huang, X, Schnoll-Sussman, F, Holloway, S, Matthews, N, Chen, X, Yu, B, Wright, J, Wadler, S. Phase II study of PS-341 (VELCADE, bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Proc ASCO GI Cancer Symposium, 2005, Abstract #31, p.98, Poster Presentation.

Ocean, AJ, Lane, ME, Xiang, Z, Huang, X, Schnoll-Sussman, F, Holloway, S, Matthews, N, Chen, X, Yu, B, Wright, J, Wadler, S. Genetic Analysis of proteasome-related pathways in advanced gastric adenocarcinomas (AGA) treated on a Phase II study with PS-341 (Velcade, bortezomib) with or without Irinotecan. Proc ASCO GI Cancer Symposium, 2005, Abstract #69, p.117, Poster Presentation.

J.D. Schwartz, M. Schwartz, M. Sung, D. Lehrer, E. Cohen, M. Kinkhabwala, S.B. Holloway, A. Siegel, A. Ocean, S. Wadler. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. Proc ASCO GI Cancer Symposium, 2006, Abstract #210, p. 190, Poster Presentation.

Ocean, AJ, Schnoll-Sussman, F., Chen, X.E., Keresztes, R., Holloway, S., Matthews, N., O’Brien, K., Christos, P., Mazumdar, M., Wadler, S. Recent Results of phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Proc ASCO GI Cancer Symposium, 2007, Abstract #45, Poster Presentation.

Ocean, AJ, O’Brien, K., Lee, J., Matthews, N., Holloway, S., Christos, P., Kung, T.S., Kaubisch, A., Chen, H., Wadler, S. Phase II trial of FOLFOX6, bevacizumab and cetuximab in patients with Colorectal Cancer. Proc ASCO 2007, Poster Presentation.

Back to topBack To Top